TOP > 外国特許検索 > AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA

AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA

外国特許コード F130007122
整理番号 S2011-0895-N0
掲載日 2013年1月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP066207
国際公開番号 WO 2013005603
国際出願日 平成24年6月26日(2012.6.26)
国際公開日 平成25年1月10日(2013.1.10)
優先権データ
  • 特願2011-147038 (2011.7.1) JP
発明の名称 (英語) AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA
発明の概要(英語) Provided are eye drops, and a subconjunctival injection drug for refractory allergic conjunctival disease, foremost for seasonal allergic conjunctivitis. This agent for prevention and/or treatment of allergic inflammation in the conjunctiva contains semaphorin-3A as an active component.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, typified by hay fever has increased over the allergic diseases, involving multiple organs, occupies about 30% of the population, a great social problem. Pollen allergic conjunctival disease patient is estimated to be about 85% and property, there is a severe cases a proportion of at least 1% (non-patent document 1). As causing an increase in these allergic diseases, air pollutants and to be associated with pointed out.
Current, anti-allergic eye drops is formulated and type 9, anti-histamine eye drops is mostly used. However, non-steroidal ophthalmic drug effect is not enough. Allergic reaction type I allergic conjunctival disease is a collective term for disease involving the conjunctiva, a variety of lesion only anti-allergic eye drops cannot be suppressed, has been formulated steroid eye drops (non-patent document 2).
On the other hand, steroid eye drops is, of the effect is large, local eye increased intraocular pressure, cataract, retinopathy, the induction of infection progression, vascular abnormalities, skin conditions, there is a strong side effects such as hirsutism, cannot be easily continued. Therefore, as a therapeutic agent is administered to the non-steroidal instead, conjunctiva steroid drug more angular peripheral nerve paraesthesia, avoid side effects such as conjunctival vascular abnormalities, strong effect are eye drops has been developed.
The functions of the immune system revealed typical semaphorin molecule is Sema3A, the functions of the nervous system in the world as guidance factor has been industriously analysis (non-patent document 3) is, immune cell migration inhibitory effects have also been reported in recent years (non-patent document 4). T cell receptor (TCR) signaling pathway or inhibition of MAP kinase signaling pathway, or actin integrated inhibition than suppressing the activation of, in addition, complex pelexin-A4 NP-1/Sema3A as receptors for the negative T cell immune response was reported to be involved in the control (non-patent document 5 and 6).
However, allergic conjunctival disease semaphorin molecule Sema3A report to the effect that is not effective.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Public University Corporation Yokohama City University
  • 発明者(英語)
  • TANAKA, Junmi
  • MIZUKI, Nobuhisa
  • GOSHIMA, Yoshio
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close